Merck announced Friday that four African countries, including the Democratic Republic of the Congo (DRC), Burundi, Ghana, and Zambia, have approved the Ebola Zaire Vaccine, ERVEBO. Approvals by these...

The U.S. Food and Drug Administration announced today the approval of Ervebo, the first FDA-approved vaccine for the prevention of Ebola virus disease (EVD), caused by Zaire ebolavirus in individuals...

The European Medicines Agency has recommended granting a conditional marketing authorisation in the European Union for Ervebo (rVSVΔG-ZEBOV-GP), the first vaccine for active immunisation of individuals...

Here is a look at some interesting infectious disease and health news, opinion and research reported across the globe: Circulating vaccine-derived poliovirus type 1 – Papua New Guinea On 26 June 2018,...

Yesterday, GeoVax Labs, Inc. announced the publication of its manuscript entitled “A Single-Dose of Modified Vaccinia Ankara Expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal...

University of Hawaii vaccine researcher Axel Lehrer, PhD, has received a nearly $6.3 million grant to test whether the Ebola vaccine formula he has developed will protect against two additional viruses...

A phase 1 randomized controlled trial has found an Ebola virus disease (EVD) vaccine, developed in Canada, was well-tolerated with no safety concerns, and high antibodies were present in participants...

An experimental Ebola vaccine was highly protective against the deadly virus in a major trial in Guinea, according to results published Thursday in The Lancet. The vaccine is the first to prevent infection...

A biopharmaceutical company collaborating with Hawai’i scientists on an Ebola vaccine has announced encouraging news about its vaccine. Tests on the vaccine, still in development, have shown it is able...

An experimental vaccine combined with an innovative way of vaccinating people has resulted in an estimated 100 percent efficacy of the vaccine against the Ebola virus in West Africa — and the approach...